The effects of TXNRD2 in vivo were reported by Caprioli et al. who observed reduced RGC death after optic nerve axotomy in experimental models of glaucoma overexpressing TXNRD2 when treated with pharmacologically induced oxidative stress [93]. The gene discussed is TXNRD2; the disease is glaucoma.